Lomitapide Production Cost Reports

The report provides a detailed analysis essential for establishing a Lomitapide production plant. It encompasses all critical aspects necessary for Lomitapide production, including the cost of Lomitapide production, Lomitapide plant cost, Lomitapide production costs, and the overall Lomitapide production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Lomitapide production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Lomitapide is a cholesterol-lowering medication used to treat people with very high inherited cholesterol levels. It is primarily used as a medication in the treatment of familial hypercholesterolemia, which is a rare genetic disorder that causes high levels of cholesterol in the blood. It works by inhibiting the production of lipoprotein particles (a protein called microsomal triglyceride transfer protein (MTP)), thereby reducing cholesterol levels in the blood.

It is generally prescribed as part of a comprehensive treatment plan to reduce the risk of cardiovascular disease. Moreover, Lomitapide is also being studied for its potential to treat other cholesterol-related conditions, particularly in cases where traditional lipid-lowering therapies are not effective. It is also being investigated for its potential applications in treating other metabolic disorders related to lipid metabolism.

The market for Lomitapide is primarily driven by its use as an important therapeutic option for patients with specific genetic conditions, which fuels its demand in the medical sector. Its application as a specialised cholesterol-lowering medication in the treatment of hypercholesterolemia to prevent high cholesterol and heart disease further boosts its demand in the pharmaceutical industry. Its involvement as a medication for treating homozygous familial hypercholesterolemia (HoFH) and other genetic disorders that require effective long-term lipid control also fuels its demand in the pharmaceutical and healthcare industries.

Its demand in the rare-disease pharmaceutical sectors for its ability to significantly reduce LDL cholesterol levels when other treatments are insufficient further supports its market growth. Rising awareness of genetic lipid disorders, improved diagnostic capabilities, and the increasing need for targeted therapies further contribute to its market growth. Industrial Lomitapide procurement is shaped by factors such as the cost and availability of key raw materials, strict regulatory requirements, and adherence to high production standards due to its classification as an orphan drug.

Raw Material for Lomitapide Production

According to the Lomitapide production plant project report, the major raw materials for Lomitapide production include 9H-fluorene-9-carboxylic acid and 1,4-dibromobutane and 2,2,2-trifluoroethylamine and 4-N-Boc-aminopiperidine.

Production Process of Lomitapide

The extensive Lomitapide production cost report consists of the following industrial production process:

1. Production via Chemical Synthesis: The production process of Lomitapide begins with converting 9H-fluorene-9-carboxylic acid into 9-(4-bromobutyl)-9H-fluorene-9-carboxylic acid through alkylation with 1,4-dibromobutane using n-butyllithium in THF. Then, this intermediate is dissolved in dichloromethane and transformed into the corresponding acid chloride using phosgene with a catalytic amount of DMF. Further, the resulting compound is coupled with 2,2,2-trifluoroethylamine to form the corresponding amide. The resulting product undergoes alkylation with 4-N-Boc-aminopiperidine in the presence of potassium carbonate in DMF. Then, the Boc group is removed using 4 N hydrochloric acid in dioxane to produce a free amine. The obtained amine is reacted with the acid chloride prepared from the target acid at low temperature in dichloromethane, using trimethylamine and a catalytic amount of DMAP. The complete process results in the formation of Lomitapide as the final compound.

Lomitapide appears as a white to off-white crystalline powder at room temperature. Its molecular formula is C39H37F6N3O2, and its molar mass is about 693.7 g/mol. Its melting point is approximately 142 degree Celsius. The density of the compound is around 1.34 g/cm³, and its boiling point is around 778 degree Celsius. The flash point of the compound is around 424 degree Celsius. Solubility is limited in non-polar solvents, and the free base shows slight solubility in some organic solvents (like methanol or DMSO). Its solubility in water is very low or negligible. It is handled with care in pharmaceutical formulations rather than as a simple inorganic solid because of its chemical complexity and hydrophobic character.